Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
CI 1033 · 3 trials · 3 indications
| Name | Type | Description |
|---|---|---|
| CI 1033 | DRUG | - |
| CI-1033 | DRUG | - |
| PACLITAXEL | DRUG | - |
| CARBOPLATIN | DRUG | - |
Inclusion Criteria: * Histologically or cytologically documented diagnosis of progressive or recurrent, locally advanced or metastatic NSCLC; a tumor that expresses at least one member of the erbB family of receptors; failed or relapsed after receiving a platinum-containing regimen as therapy; at l...
CI 1033 is an investigational oral small molecule that was studied in oncology for metastatic breast cancer and advanced non-small cell lung cancer. It was evaluated as a single agent in Phase 2 studies and in combination with paclitaxel and carboplatin as first line chemotherapy in NSCLC patients.
CI 1033 was developed by Pfizer, Inc., which trades on the New York Stock Exchange under the ticker PFE. Pfizer sponsored the clinical program evaluating the compound in breast cancer and non-small cell lung cancer, including a Phase 2 monotherapy study and a Phase 1 combination study.
CI 1033 reached Phase 2 clinical development. It is investigational and was studied in completed Phase 1 and Phase 2 trials; the program's registered studies are all listed as completed, with no active trials. The Phase 2 studies enrolled patients with metastatic breast cancer and advanced non-small cell lung cancer.
CI 1033 was studied in NCT00051051, a Phase 2 trial in metastatic Stage IV breast cancer that enrolled 168 patients across the United States and Europe, and NCT00050830, a randomized Phase 2 trial in advanced non-small cell lung cancer. A Phase 1 trial, NCT00174356, tested CI-1033 with paclitaxel and carboplatin in NSCLC.
Yes. CI 1033 and CI-1033 refer to the same investigational compound developed by Pfizer. The hyphenated form, CI-1033, appears in the registered clinical trial titles, including the Phase 2 breast cancer study and the Phase 2 non-small cell lung cancer study, while CI 1033 is the unhyphenated spelling of the same drug name.
The CI 1033 clinical program enrolled patients across three completed studies. The Phase 2 breast cancer trial enrolled 168 patients, the randomized Phase 2 non-small cell lung cancer trial enrolled 163 patients, and the Phase 1 combination trial with paclitaxel and carboplatin enrolled 39 patients with NSCLC.